Twists and turns to translating 4-1BB cancer immunotherapy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 31189719.
- Also identified by DOI 10.1126/scitranslmed.aax4738.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Previous shortcomings of CD137-targeted immunotherapy may be overcome by engineered bispecific agents (Claus <i>et al</i>, this issue).
Medical subject headings
- Antibodies, Bispecific
- Neoplasms